The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.
This grant is designed to expedite the progress of cancer-related interventions aimed at advancing health equity and representing the diversity of populations and contexts across the U.S. It focuses on supporting research that evaluates the impact of cancer-related interventions on various outcomes throughout the cancer control continuum through pragmatic trial study designs. The grant employs a UG3/UH3 phased cooperative agreement mechanism, with the UG3 phase dedicated to refining interventions and finalizing study preparations and the UH3 phase aimed at conducting the pragmatic trials. Funding for the UG3 phase is capped at $500,000 in direct costs annually, while the UH3 phase has a limit of $750,000 in direct costs per year. The project can last up to two years in the UG3 phase and four years in the UH3 phase.